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Six patients, five with acute myeloid leukemia (AML) and one with a myelodysplastic 
syndrome (MDS), were found to have monosomy 7 by conventional cytogenetics at di- 
agnosis. Repetitive DNA sequences from the heterochromatic region of human chromo- 
somes 1 and 7 were used as probes for in situ hybridization experiments on interphase 
cells of these patients. A double hybridization protocol was used to reveal the particular 
chromosomes as distinct spots or clusters of signals within interphase nuclei. The chro- 
mosome 1 sequence served as an internal control. Simultaneous detection of the se- 
quences showed the presence of two normal number 1 chromosomes and a missing 7 
chromosome from individual cells. While cytogenetic preparations showed only -7 
metaphases in 3 AML and 1 MDS patients, in situ hybridization of interphase cells showed 
many normal cells as well as the presence of -7 in fully mature granulocytes. One AML 
patient studied in remission showed only normal metaphases yet had 9% interphase cells 
with a missing 7 and relapsed within 3 months. We conclude that examination of inter- 
phase cells by in situ hybridization provides clinically useful data since every cell includ- 
ing mature granulocytes can be examined, the lineage of a cell can be determined, and 
efficacy of differentiation therapy can be evaluated. 
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INTRODUCTION 
The possibility that leukemic cells of patients with 
myeloid leukemias can be induced to differentiate has 
been an appealing alternative to aggressive remission 
induction chemotherapy [1,2]. Before the efficacy of a 
variety of inducing agents can be practically tested how- 
ever, direct proof that a mature cell has actually been 
derived from the leukemic clone is required. Since ma- 
ture cells do not enter mitosis, classical cytogenetic proof 
of such clonal origin cannot be obtained. Recently, it has 
become possible to identify individual chromosomes in 
interphase cells [3-61. This is accomplished by using in 
situ hybridization with cloned DNA probes that detect 
specific repetitive target DNA sequences present in in- 
dividual chromosomes. By using multicolor detection of 
multiple chromosome specific DNA probes, more than 
one chromosome can be identified in an individual in- 
terphase cell [7]. 
We identified five patients with acute myeloid leuke- 
mia (AML) and one with a myelodysplastic syndrome 
(MDS) who had monosomy 7 detected by conventional 
cytogenetic techniques. Using a probe (pa7tl) specific 
for the pericentromeric region of chromosome 7, we 
were able to demonstrate the presence of -7 abnormality 
in interphase cells of these individuals. Simultaneous de- 
tection of two different nucleic acid sequences demon- 
strated the presence of two normal number 1 chromo- 
somes and a missing chromosome 7 in individual cells. 
This report describes the cytogenetic data and in situ 
hybridization findings in these six patients with AML 
and MDS. 
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MATERIALS AND METHODS 
Six patients with myeloid disorders were the subject of 
this study. Five individuals had a diagnosis of AML and 
one patient suffered from MDS. Bone marrow (BM) as- 
pirates and/or peripheral blood (PB) samples were ob- 
tained from every patient into a plastic syringe contain- 
ing 2 ml of 6% sodium citrate. Informed consent was 
obtained from each patient. Cytogenetic studies were 
performed on short-term cultures of heparinized samples 
by using standard G-banding methods. For identification 
of specific chromosomes in interphase cells, the follow- 
ing methods were utilized: 
Sample Preparation 
Bone marrow aspirates or peripheral blood samples 
were layered on Ficoll Hypaque (specific gravity 1.077) 
and centrifuged at 1,200g for 30 min. The light density 
cells were recovered, washed in PBS, and treated with 
hypotonic KCl (0.075 M) for 30 min at 37°C or depos- 
ited onto precleaned glass microscope slides by cytocen- 
trifugation. Subsequently the cells were fixed with sev- 
eral changes of methanol/acetic acid (3:1, vh ) .  Cells 
fixed in suspension were dropped onto ethanol cleaned 
slides. The slides were dried overnight in a hot air oven 
at 65°C and stored in sealed boxes at 4°C until use. 
DNA Probes 
Probe puc 1.77 represents a 1.77 KB EcoRI fragment 
of human satellite I11 DNA family cloned in puc 9 [8] and 
is located predominantly on chromosome 1. The probe 
pa7tl contains a 680 bp EcoRI fragment of alphoid DNA 
cloned in puc9 and is specific for chromosome 7 using 
higher stringency conditions [9]. After in situ hybridiza- 
tion both sequences light up only the pericentromeric 
hetero-chromatic region of their corresponding chromo- 
somes. 
Probe pa7tl was chemically modified by nick transla- 
tion with biotin-labeled deoxyuridine triphosphate (bio- 
11-dUTP) (BRL) to a mean size of 200-400 bp [lo]; puc 
1.77 was modified by treatment with 2-acetylaminoflu- 
orene (AAF) according to method of Landegent et al. 
[ 1 I] and sonicated in 10 mM Tris/ImMEDTA buffer to 
yield 200-400 bp fragments as analyzed by gel electro- 
phoresis. 
In Situ Hybridization 
Hybridizations were performed as described 171 by 
using 60% Formamide/2 X SSC (1 X SSC is 0.15 M NaCI, 
0.015 M sodium citrate) to suppress non-specific chro- 
mosome hybridization. The labeled probes puc 1.77 
(AAF) and pa7tl (Biotin) were used in combination at a 
final concentration of 1-2 pg/ml. The hybridization mix- 
ture was applied to the slides under a coverslip (3 pl/cm2) 
which was sealed with rubber cement. Denaturation of 
probe and cellular target DNA was carried out by heating 
the slides to 80°C for 10 min in a hot air oven. Hybrid- 
ization was carried out for 16-18 hr in a moist chamber 
at 37°C. After hybridization the slides were washed at 
45°C (50% Formamide/2 x SSC, pH 7.0, three times for 
10 min each followed by washes with 4 X SSC, pH 7.0, 
twice for 10 min each, and finally a wash with 0.1 X SSC, 
pH 7.0, at 65"C, twice for 10 min each) and immersed in 
PN-buffer (0.1 M sodium phosphate, 0.05% Nonidet P- 
40, pH 8.0). The stringency of hybridization conditions 
is crucial in order to avoid cross hybridization with related 
sub-families present on other chromosomes. When the 
stringency is somewhat decreased, hybridization signals 
become apparent on other chromosomes [3]. 
Cytochemical Detection 
Detection of target sites was carried out as described 
171 by using streptavidin (2 pg/ml) combined with mouse 
monoclonal antibodies against AAF (1:300, gift of R.A. 
Baan, The Netherlands) in the primary reaction. The 
secondary reaction included biotinylated alkaline phos- 
phatase combined with goat antimouse IgG conjugated 
with fluorescein isothiocyanate (FITC) ( I  :200, Sigma). 
Alkaline phosphatase was developed with nitro blue tet- 
razolium choride (NBT) and 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP) for 1 hr at 37°C [7], counterstained 
with DAPI (200 mg/ml) for total DNA, and mounted in 
an antifade solution. Microphotographs were taken on a 
Nikon microscope equipped for FITC and DAPI fluores- 
cence. A small amount of transmitted light was used to 
improve the photographic signal of the alkaline phos- 
phatase reaction in the DAPI stained nuclei. 
RESULTS 
Table I summarizes the clinical data on the six patients 
who are the subject of this report. Five had a diagnosis of 
AML. Three were studied at the time of relapse or re- 
fractory leukemia, one (JG) during complete remission 
(CR), and one (PS) after she received an allogeneic bone 
marrow transplant from her HLA-matched brother. The 
last patient in Table I (TA) has had a diagnosis of my- 
elodysplasia for 5 yr with an indolent, relatively benign 
course. 
Cytogenetic examination with conventional G-band- 
ing revealed the presence of monosomy 7 in all of these 
patients prior to chemotherapy. The first three AML pa- 
tients were studied for interphase cytogenetics when they 
had active leukemia. The -7 abnormality was noted in 
almost all metaphases (loo%, loo%, and 95% respec- 
tively) (Table I). JG and PS were studied during com- 
plete remission and post bone marrow transplantation 
respectively. They both demonstrated only normal 
metaphases even though each had monosomy 7 in 100% 
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TABLE 1. Clinical Characteristics, In Situ Hybridization, and Cytogenetic Data on Patients With Myeloid Disorders’ 
Differential in situ hybridization, 
9% (No. interphase cells) 
-7 cells, N cells, Cytogenetics, % 
Sample Dx 9% Lymphs 2 chromosome I ,  2 chromosome I ,  (No. metaphases) 
No. Name PBIBM FAB type Status % blast % PMN + Monos I chromosome 7 2 chromosome 7 7 cells N cells 
1 SW PB AML Refr. Dis. 86 0 14 82 8 100 0 
FAB MI (172) (16) (20) (0) 
2 RS PB AML Refr. Dis. 73 17 5 75 15 100 0 
3 JC BM AML REL 46 4 40 77 12 95 5 
FAB M I  ( 160) (25) (19) (1 )  
0 100 4 JG PB AML REM. 0 59 37 9 74 
FAB M4 (18) (153) (0)  (20) 
5 PS BM AML SIP BM 3 21 19 4 80 0 100 
FAB M7 Transplt. (8) (167) (0) (30) 
6 TA PB MDS MDS 0 9 87 (117) (158) 100 0 
58 29 (20) (0) 
PB 2 12 86 63 25 I00 0 
FAB M2 ( 162) (33)  (27) (0) 
( 124) (49) 
*PB = peripheral blood; BM = bone marrow; Dx = diagnosis; AML = acute myeloid leukemia; Refr. Dis. = refractory disease; REM = remission; 
N cells = normal cells; S/P BM Transplt. = status post allogeneic bone marrow transplant; MDS = myelodysplastic syndrome; PMN = polymor- 
phonuclear leukocytes; Lymphs = lymphocytes; Monos = monocytes. 
metaphases of bone marrow specimens examined 3 
months and 7 months prior to this study. Finally, TA has 
had several cytogenetic examinations in the last few 
years. He has consistently demonstrated the presence of 
monosomy 7 in all the metaphases examined during this 
time. Occasionally, TA has hypodiploid cells which 
demonstrate random chromosome loss in addition to the 
monosomy 7. It is worthwhile to note that TA has not 
received any cytotoxic chemotherapy. Additional chro- 
mosomal abnormalities were only identified in patient JG 
who had inv( 16) in addition to monosomy 7 in 7 of 11 
metaphases at the time of diagnosis. Occasional random 
loss of chromosomes was observed in other patients, but 
no other definite clonal abnormalities were identified. 
Table I1 presents the numberical scoring of interphase 
cells obtained from either “normal” blood or bone mar- 
row as well as the details of results obtained in all pa- 
tients being reported in Table I. It can be seen that even 
in normal samples, there is a range of error since up to 
5% cells showed monosomy of either chromosome 1 or 
7. Confusing data could be a result of the two signals 
being superimposed (monosomy), incomplete hybridiza- 
tion, or non-specific binding of the probe (trisomy, etc.). 
Thus, data need to be interpreted with caution where 
small percentages of cells are being considered as being 
representative of a “clone.” 
Figure l a  and b demonstrates detection of the two 
chromosomes by the in situ hybridization method. It can 
be seen clearly that the interphase cells, which represent 
mature myeloid cells, all have two normal chromosomes 
1 as identified by the FITC label in Figure la.  On the other 
hand, there is only one chromosome 7 seen in all of these 
cells as shown by the blue staining of alkaline phosphatase 
in Figure lb .  Morphological recognition that these were 
mature myeloid cells was possible because of counter- 
staining with DAPI which outlined the nuclei of these 
cells distinctly (Fig. lb). The cellular integrity was found 
to be more efficiently preserved in hybridizations carried 
out on cells deposited by cytocentrifugation of single cell 
suspensions than by other techniques. 
Table I also summarizes the in situ hybridization data 
along with the clinical and cytogenetic information on 
these six patients. The first three patients were studied 
during florid AML. Almost all metaphase cells examined 
by G-banding showed monosomy 7 (Table I). By in situ 
hybridization, we detected monosomy 7 in the majority of 
blasts (82, 75, and 77%), but 8, 15, and 12% cells re- 
spectively did not show monosomy 7. These patients were 
noted to have 14%, 22%, and 44% mature granulocytes 
or lymphocytes and monocytes on differential counts. 
Thus, it is not surprising that interphase analysis showed 
the presence of many normal cells that did not contain the 
-7 phenotype. The two patients studied at remission or 
following bone marrow transplant had normal cytogenet- 
ics and 76% and 80% normal interphase chromosomes 1 
and 7 respectively. A small number of cells (9%) were 
identified in the PB of patient JG with a monosomy 7 by 
in situ hybridization. Since there were no circulating 
blasts in the blood of this patient, only mature cells from 
PB were available for study. In control experiments using 
normal lymphocytes and BM cells we have found ap- 
proximately 4% nuclei showing one spot with probe pa7tl 
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TABLE II. Frequency of Chromosomes 1 and 7 Signals Detected in Interphase Cells of “Normal” Controls and Patient Samples 
Corresponding to Table I 
Interphase cells with frequency of chromosomes I and 7 signals per cell 
No. chromosome 7 signals: 1 I 1 1  2 2 2 3 3 3 3 4 4 Total cells 
No. chromosome I signals: 1 2 3 4  1 2 3 I 2 3 4 1 2 analyzed 
Controls 
1 .  Normal PB 5 l I O O 1 0 1 6 6 6 1 5 1 0 0 2  207 
2. Normal BM 5 0 0 0 I I  176 6 0 1 5  1 0  2 207 
Patients 
I .  sw 
2. RS 
3. JC 
4. JG 
5 .  PS 
6. TA 
9 172 7 0 4 16 2 I 0  0 0 0 0 21 1 
6 162 3 0 3 33 2 2 2 3 0 0 0 216 
8 160 7 0 3 25 2 0 1 I 0  0 0 207 
5 1 8 0 0 1 0 1 5 3 6 1 5 2 0 0 0  200 
6 X I 0  9 167 7 0 6 2 0 0 2 208 
7 117 I 0 I 58 4 2 4 2 0 0 0 202 
1 1  124 0 0 8 49 0 2 2 1 0  0 1 I98 
in a total of 1,000 nuclei analyzed by using the double 
hybridization protocol. Therefore whether 9% of cells in 
JG with the -7 abnormality indicates the persistence of 
the leukemic clone that can differentiate or is due to 
incomplete hybridization of the probe cannot be deter- 
mined at the present time. 
Patient TA, who has had an indolent myelodysplastic 
syndrome for the last 5 yr, has been studied twice for in 
situ hybridization. While he has only normal mature cells 
in the blood, 58% and 63% of these demonstrate the 
presence of monosomy 7 (Table I). Clearly, the mature 
cells in this case were derived from the abnormal clone. 
The fact that these -7 cells have retained their ability to 
differentiate in vivo could explain the relatively benign 
course of his disease. 
DISCUSSION 
AML is a monoclonal disease in which a hematopoi- 
etic precursor cell has undergone malignant transforma- 
tion [ 12,131. Remission is usually achieved by intensive 
chemotherapy which reduces the leukemic burden to a 
level which is low enough to allow normal hematopoiesis 
to resume. It has become apparent over the last two 
decades, however, that mechanisms other than produc- 
tion of aplasia and repopulation by normal cells may be 
operative in the achievement of a complete remission 
(CR). For example, several cases of acute promyelocytic 
leukemia have been described recently where remission 
was achieved without intermediate marrow hypoplasia 
following intensive combination chemotherapy [ 141. 
This suggests that the induction of differentiation may be 
a likely mechanism of response. While the possibility of 
inducing leukemic cells to differentiate has been a sub- 
ject of ongoing discussion, evidence that mature cells 
during remission may actually be derived from a leuke- 
mic clone has only recently appeared. 
Two different types of studies have provided proof of 
differentiation in leukemic cells. Firstly, by studying pa- 
tients who were heterozygous for the X-chromosome- 
linked enzyme glucose-6-phosphate dehydrogenase 
(G6PD), Fialkow et al. have documented clonal devel- 
opment, stem cell differentiation, and monoclonality in 
and during complete remissions in AML patients [ 15,161. 
Secondly, Fearon et al. have used recombinant DNA 
probes to detect clonal populations of granulocytes in 
AML patients and have provided evidence that in some 
patients, leukemic blast cells differentiate to form mature 
cells [17]. However, while G6PD studies can be per- 
formed on a rare individual for obvious reasons, using 
DNA probes on Southern blots such as those used by 
Fearon et al. only provides information on a population 
of cells as a whole. 
The in situ hybridization techniques we have used to 
identify chromosomes in interphase cells are superior to 
other techniques because they provide information on 
individual cells and can also be performed when only a 
few cells are available. Data provided in the present re- 
port demonstrate the feasibility of studying interphase 
cells in patients with active leukemia during complete 
remission and myelodysplastic disorders. We identified 
five patients with AML and one with MDS all of whom 
had demonstrated monosomy 7 by conventional G- 
banding techniques. Two probes against repetitive DNA 
sequences on chromosomes 1 and 7 provided the follow- 
ing pertinent data in interphase cells of these patients. 
First, in patients with active leukemia 7 5 4 0 %  of in- 
terphase blast cells contained only one chromosome 7 
and two chromosomes 1 as expected. This interphase 
identification of chromosomes seems more sensitive than 
conventional metaphase preparations because in these 
three patients (SW, RS, and JC in Table I), only one 
normal metaphase was identified in patient JC, yet in situ 
hybridization of interphase cells demonstrated normal 
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Fig. 1. lnterphase nuclei from a patient with monosomy 7 after double hybridization with 
(a) chromosome 1 (AAF/FITC); and (b) chromosome 7 (Biotin/alkaline phosphatase) coun- 
terstained with DAPI. 
cells in all three patients in addition to those containing 
monosomy 7. Second, in the patients JG and PS, only 
normal metaphases were observed by cytogenetic anal- 
ysis, however, at the time of in situ hybridization, 9% 
and 4% cells showed monosomy 7 respectively. JG re- 
lapsed within 3 months of this finding. The significance 
of finding a few cells with monosomy 7 in patient PS are 
still unclear. It must be remembered, however, that a 
small percentage of monosomy 7 cells may be within the 
range of error; for example, a small percentage of inter- 
phase nuclei may have both chromosome 7 signals lying 
in the same plane. In addition, incomplete hybridization 
or non-specific binding of probes may give rise to false 
signals. As seen in Table 11, up to 5 %  “normal” periph- 
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era1 blood or bone marrow cells showed monosomy for 
either chromosome 7 or chromosome 1. Therefore cau- 
tion is indicated in order to avoid overinterpretation of 
data. Patient PS has received an allogeneic bone marrow 
transplant from her HLA-matched brother, and her cy- 
togenetics now reveal a normal 46XY karyotype. It will 
be interesting to use a probe specific for the X chromo- 
some and chromosome 7 simultaneously in this patient to 
see whether the monosomy 7 which is seen in very few 
cells at this time is present in donor cells or whether some 
of the patient’s own cells survived due to an ineffectual 
preparative regimen. These studies are currently under- 
way in our laboratory. 
Finally, TA, who has had a myelodysplastic syndrome 
(Table I) for 5 yr, clearly has cells that have monosomy 
7, yet are fully differentiated. Obviously, monosomy 7 
may not be the only abnormality in this patient since we 
have little information regarding the numberical status of 
other chromosomes in interphase cells. Interestingly 
enough, the presence of monosomy 7 in a cell does not 
necessarily mean a loss of ability to differentiate. Per- 
haps, the fact that the differentiation pathway is intact in 
these cells is one explanation for the rather benign nature 
of his illness. We have already reported that in vivo 
differentiation as documented by the appearance of bro- 
modeoxyuridine (BrdU) in granulocytes obtained by se- 
rial sampling in AML patients is a good prognostic sign 
[ 1 81. Once again, the fact that the maturation pathway is 
intact in these individuals seems to be associated with a 
less aggressive type of leukemia [18]. We have now 
combined interphase cytogenetics with the use of a 
monoclonal anti-BrdU antibody in a triple label tech- 
nique which will permit more detailed cell cycle studies 
in in situ hybridized cells. 
Therefore, in summary, while conventional cytogenet- 
ics provide information on mitotic cells, which usually 
constitute a very small proportion of the cells in a pop- 
ulation, interphase cytogenetics can examine every cell 
including terminally differentiated cells such as granulo- 
cytes. With similar information collected on large num- 
bers of AML patients, the definition of “complete re- 
mission” may have to be revised in this disease. 
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